Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on April 9, 2020. The report addresses a specific amendment to the company's executive compensation structure regarding the Perrigo Employee Severance Programme-Ireland, administered by its subsidiary, Perrigo Pharma International D.A.C.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly focused on a governance and compensation policy update.
Material Changes
On April 9, 2020, the Company amended and restated the Perrigo Employee Severance Programme-Ireland to remove the excise tax gross-up payment provision for eligible executives. Previously, the Programme provided statutory redundancy pay, notice periods, and an ex gratia payment equal to 2.5 times the sum of 52 weeks of pay and the target annual bonus. Under the amended terms, eligible executives will no longer be entitled to an excise tax gross-up payment.
Management Commentary and Risks
Management stated that this amendment is consistent with the Company's longstanding pay-for-performance compensation philosophy. The filing does not disclose new risks, contingencies, or unusual items beyond the change in severance terms.
Key Facts for Investor Verification
- The excise tax gross-up provision has been eliminated from the Irish executive severance programme.
- The change applies to eligible executive officers under Irish employment agreements facing redundancy, termination without cause, relocation, or material diminution of authority or salary.
- The core severance calculation (2.5x sum of 52 weeks' pay and target bonus) remains in effect, excluding the tax gross-up.
- No financial impact figures or guidance were provided in this filing.